Spyglass Pharma, Inc. (SGP) Stock Price & Analysis
Spyglass Pharma, Inc. (SGP) fell 0.07% to USD 28.92 as of September 8, 2026 at 23:41 UTC, according to Nexqual real-time market data.
SGP last closed at USD 28.94; the session ranged USD 27.82–30.05 on volume of 119,317 shares. Market capitalization is $967.32M, with a 52-week range of USD 17.06–32.44 (NMS). Source: Nexqual, September 8, 2026 at 23:41 UTC.
Key Statistics (as of September 8, 2026 at 23:41 UTC)
| Price | USD 28.92 |
|---|---|
| Change | ▼ 0.07% (down) |
| Previous Close | USD 28.94 |
| Open | USD 28.64 |
| Day Range | USD 27.82 – 30.05 |
| 52-Week Range | USD 17.06 – 32.44 |
| Volume | 119,317 shares |
| Market Cap | $967.32M |
| Exchange | NMS |
Technical Analysis (SGP)
Nexqual's technical model rates SGP "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of September 8, 2026 at 23:41 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 75.68 (overbought) |
| vs SMA50 | Above (USD 23.53) |
| MACD | 1.41 (positive) |
Analyst Ratings (SGP)
Wall Street analysts rate SGP "None" based on 6 analysts, with a mean price target of USD 44 (range USD 37–62), per Nexqual as of September 8, 2026 at 23:41 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 44 |
| High Target | USD 62 |
| Low Target | USD 37 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (SGP)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.62 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.59 vs est -0.55 ▼ miss |
| 2026-03-31 | USD -0.69 vs est -0.36 ▼ miss |
Source: Nexqual, September 8, 2026 at 23:41 UTC.
Financials & Fundamentals (SGP)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.7 |
| Current Ratio | 25.06 |
| Total Cash | $234.19M |
| Total Debt | $1.63M |
Source: Nexqual, September 8, 2026 at 23:41 UTC.
Financial Health Score (SGP)
Nexqual rates Spyglass Pharma, Inc.'s overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 23:41 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $234M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$47M |
| Efficiency | Mixed — No data |
Ownership (SGP)
| Insider Ownership | +4.28% |
|---|---|
| Institutional Ownership | +94.69% |
| Shares Outstanding | 33.45M |
| Float | 6.50M |
| Short % of Float | +10.24% |
Source: Nexqual, September 8, 2026 at 23:41 UTC.
Leadership (SGP)
Spyglass Pharma, Inc. is led by Patrick H. Mooney (age 51), CEO & Director, per Nexqual as of September 8, 2026 at 23:41 UTC.
| CEO & Director | Patrick H. Mooney (age 51) |
|---|---|
| Co-Founder, President, Chief Medical Officer & Executive Chairman | Malik Y. Kahook (age 50) |
| Co-founder & Chief Technology Advisor | Glenn Sussman (age 61) |
| Chief Financial Officer | Jean-Frederic Viret (age 59) |
| Chief Operating Officer | James Robert Dennewill (age 44) |
Major Backers & Investors (SGP)
Notable institutional backers of Spyglass Pharma, Inc. include RA Capital Management, L.P., NEA Management Company, LLC, Sands Capital Alternatives, LLC, according to Nexqual as of September 8, 2026 at 23:41 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 23.99% |
| NEA Management Company, LLC | 22.11% |
| Sands Capital Alternatives, LLC | 7.48% |
| Samsara BioCapital, LLC | 6.31% |
| JPMorgan | 2.75% |
| Price (T.Rowe) Associates Inc | 2.02% |
| Vestal Point Capital, LP | 2% |
| Deerfield Management Company, L.P | 1.65% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 2.84% |
Source: Nexqual, September 8, 2026 at 23:41 UTC.
From Spyglass Pharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions.
- The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients.
- It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost.
- SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DNA | Ginkgo Bioworks Holdings, Inc. | USD 6.94 | ▼ 0.14% |
| BMY | Bristol-Myers Squibb Company | USD 64.69 | ▼ 4.99% |
| KG | Kestrel Group, Ltd. | USD 6.98 | ▼ 7.92% |
| SLE | Super League Enterprise, Inc. | USD 4.67 | ▲ 32.67% |
| NVS | Novartis AG | USD 137.7 | ▼ 15.57% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 23:41 UTC. This page is informational and not investment advice.